Effectiveness of clozapine, haloperidol and chlorpromazine in schizophrenia during a five-year period
| Autor: | Mihailo Pantović, Suzana D. Jovic, Boris Ravanic, D. Ravanic, Maja Pantović, Slavica Djukic Dejanovic, Dragan Milovanovic, Vesna Pantovic, Vladimir Jakovljevic, Vladimir Janjic |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male medicine.medical_specialty Time Factors Chlorpromazine Drug Administration Schedule Internal medicine Haloperidol Humans Medicine Prospective Studies antipsychotics drugs Adverse effect Prospective cohort study Clozapine business.industry Low dose medicine.disease clinical practice schizophrenia Treatment Outcome Neurology Schizophrenia Female Chronic schizophrenia Neurology (clinical) business long-term outcomes Antipsychotic Agents medicine.drug |
| Zdroj: | Arquivos de Neuro-Psiquiatria v.67 n.2a 2009 Arquivos de neuro-psiquiatria Academia Brasileira de Neurologia instacron:ABNEURO |
| ISSN: | 0004-282X |
| Popis: | OBJECTIVE: The aim of our study was to evaluate the effects of low doses of clozapine in flexible regime in comparison with haloperidol and chlorpromazine in long term. METHOD: The naturalistic study was prospective, active-controlled with 325 adult outpatients of both genders (140 females), with mean year age of 34.8 (range 21-57), suffering from chronic schizophrenia. The first onset of illness was at the mean of 27.9 years (range 17-38), and subjects had the mean year age of 4.1±0.5 previous relapses. The patients were allocated to receive haloperidol (105 subjects, dose range 2-15 mg), chlorpromazine (n=105, 100-400 mg) or clozapine (n=115, 75-600 mg). The scores of psychometric instruments (GWB, PANSS, CGI) were regularly assessed during 5 year period. RESULTS: The sixty-six responders were included in per-protocol analysis: 12, 10 and 16 with positive and 7, 6 and 15 with negative schizophrenic syndrome in haloperidol, chlorpromazine and clozapine group, respectively. The statistically significant differences in all psychometric scores was found, for both schizophrenic syndromes, favoring clozapine. The distribution of eighteen different types of adverse events, which we noted, were significantly different among treatment groups ( χ2=315.7, df=34, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|